Latest Market Share News

MyEco Group Ltd reported an 8.6% rise in FY25 sales driven by strong growth in its global MyEco® product line and new UK retail partnerships, while navigating challenges in resin markets and US tariffs.

VBX Limited has successfully listed on the ASX and revealed strong preliminary feasibility results for its Wuudagu Bauxite Project, positioning itself to capitalize on rising bauxite demand and supply uncertainties.

Mach7 Technologies maintains its FY25 revenue growth guidance with strong recurring revenue gains, despite a modest shortfall in contracted annual recurring revenue. The company also advances its share buyback program, signaling confidence in its financial position.

Telix Pharmaceuticals has achieved a key milestone with its next-generation prostate cancer imaging agent, Gozellix, receiving a permanent HCPCS code from U.S. Medicare. This paves the way for broader reimbursement and market adoption starting October 2025.

Brookside Energy announces an on-market share buy-back of up to 4.8 million shares, aiming to return capital and support its growth strategy amid evolving market conditions.

Stealth Group Holdings has secured exclusive distribution rights for major global consumer brands in Australia and New Zealand, aiming to accelerate revenue growth and expand its digital footprint.

The Calmer Co. International Limited has reported a striking 86% revenue jump to over AU$8 million in FY25, propelled by diversified sales channels and a strategic US expansion highlighted by new flavoured kava shots launched exclusively on Amazon USA.

The Federal Court has approved Dollarama’s acquisition of The Reject Shop, triggering a suspension of TRS shares on the ASX and setting the stage for upcoming cash payments to shareholders.

Harvest Technology Group has raised $500,000 through unsecured convertible notes with a 15% annual interest rate, supporting its strategic three-year profit plan. The notes include attached options exercisable over two years, pending shareholder approval.

Paradigm Biopharmaceuticals has locked in a $27 million USD convertible note facility to fully fund its pivotal Phase 3 trial for knee osteoarthritis, ensuring operational momentum through key clinical milestones.

Computershare has wrapped up its $750 million on-market share buy-back, cancelling over 25 million shares and signaling a strategic pivot towards dividends as the preferred shareholder reward.

Southern Cross Media Group has finalized the sale of its remaining television assets, fully committing to its 'All About Audio' strategy with a 5% rise in audio revenues for FY25 and a renewed focus on debt reduction and dividends.